GTM Playbook for Dermatology Practices in 2027

Direct Answer

A profitable private dermatology practice in 2027 runs three revenue engines in parallel: medical derm (insurance, ~55% of visits, $1.3M revenue per FTE physician), Mohs and procedural (8-15 wRVUs per case, 2-3 cases per day, the highest-margin insurance line), and cosmetic cash-pay (Botox at $13-$18/unit, fillers at $650-$1,100/syringe, the line that lifts a derm practice from $1.3M to $1.8M+ per FTE).

The GTM playbook is: Google Business Profile + reviews for medical acquisition, Instagram + Allē/ASPIRE loyalty for cosmetic acquisition, PA/NP leverage at $165K base + production bonus, ModMed EMA or Nextech as the operating spine, and an aesthetic membership at $99-$199/month to lock in recurring revenue.

1. Patient Acquisition — How New Visits Actually Arrive in 2027

The acquisition mix in private derm has split into two parallel funnels that share almost no tactics. Medical patients come from search and PCP referrals. Cosmetic patients come from Instagram, Allē, and member-of-a-friend referrals.

Practices that try to run one funnel for both lines underperform on both, because the buyer mindset is fundamentally different — a medical patient is solving a problem and wants speed and credibility, while a cosmetic patient is buying an aspirational outcome and wants social proof.

1.1 The Medical Funnel — Google Is the Acquisition Engine

77% of patients Google a dermatologist before booking, and "dermatologist near me" plus "acne specialist [city]" are the two queries that drive the bulk of new medical visits. The 2027 medical funnel is: Google Business Profile (claimed, complete, weekly posts), reviews (target 4.7+ stars, 200+ reviews per location), website with online booking (Phreesia or NexHealth widget), and PCP referral relationships (quarterly lunch with the top 10 referring PCPs).

The benchmark review velocity is 8-12 new Google reviews per month per provider. Practices below that drift down the local pack. Use Weave ($499/month per location) or Birdeye ($299/month) for automated review requests.

Expect 60-90 days before a fresh GBP and review program shows up as measurable booked-visit lift. Pair the GBP push with schema markup on the website for MedicalBusiness and Physician entities — it lifts the rich-result rate 15-25% in suburban metros where the local pack is contested.

1.2 The Cosmetic Funnel — Instagram, Allē, and the Referring Patient

Cosmetic acquisition runs on before/after content and loyalty currency. The default 2027 stack is: Instagram (4-6 posts/week, Reels weighted), Allergan Allē enrollment at every Botox visit (patients earn points, redeem on next visit, retention jumps 25-40%), and Galderma ASPIRE for Dysport/Restylane practices.

Layer in a patient referral program — $50 credit to the referrer, $50 to the new patient — and cost per acquired cosmetic patient drops to $40-$80, versus $120-$220 through paid Meta or Google ads. The most under-used 2027 cosmetic channel is email reactivation — a quarterly campaign to lapsed cosmetic patients with a $50 toxin credit typically reactivates 8-14% of the list at near-zero incremental cost.

1.3 Booked-Visit Conversion — The 30-Second Phone Window

The single biggest acquisition leak in private derm is the front desk. Industry benchmark is roughly 40% of inbound calls go to voicemail or get a 4+ minute hold during peak hours, and those callers book elsewhere. Fix the leak with NexHealth, Klara, or Weave for online booking and two-way SMS, and you typically recover 15-25% of inbound demand that was previously lost.

The supporting metric to track weekly is call-to-booked-visit conversion rate — healthy practices run 65-75%, broken front desks run 35-45%, and the gap is almost always answer-speed and follow-up SMS within 5 minutes on missed calls.

1.4 PCP Referral Discipline

PCP referrals still drive 30-45% of new medical patients in suburban markets. The 2027 discipline: build a named list of the top 25 referring PCPs per location, send a same-day HIPAA-secure consult note for every referred patient, host a quarterly CME lunch, and run a bi-annual referral leaderboard report internally.

Systematized PCP outreach typically grows referred visits 15-25% YoY with no added marketing spend.

2. Pricing & Service Mix — The Three Lines That Drive 2027 Economics

Private derm pricing in 2027 is payer-set on the medical side, market-set on the cosmetic side, and CMS-set with Mohs. The art is mix management, not list-price negotiation. The owner-operator job is to push every chair-hour toward the highest-margin compatible service for that patient.

2.1 Medical Derm Pricing — Fee Schedule and Net Collection Rate

Medical visits average $185-$240 per visit in commercial-payer-heavy markets and $95-$140 in Medicare-heavy markets. The benchmark net collection rate is 96%+; anything below 94% signals coding, denial-management, or front-end eligibility failure. Use Waystar ($350-$600/month) or AdvancedMD billing to drive eligibility checks at booking — front-end eligibility failure on a single Mohs case can mean $2,000-$5,000+ in written-off charges.

Negotiate commercial payer contracts every 24 months, not annually — leverage patient volume, Mohs surgical capability, and same-week access as the three commercial bargaining chips that earn 4-8% rate uplift per cycle.

2.2 Mohs Surgery — The Highest-Margin Insurance Line

A typical Mohs case generates 8-15 wRVUs (vs. 1-3 for a standard derm visit). 2-3 Mohs cases per day combined with general clinic produces 11,000-13,500 annual wRVUs per Mohs surgeon, which translates to $650K-$900K+ in physician compensation and well over $1.5M in collections per Mohs FTE.

The bottleneck is pathology turnaround and OR room utilization, not demand — ~850,000 Mohs cases are performed in the U.S. Annually and demand is growing 4-6% per year with the aging population. The 2027 capital investment to expand Mohs throughput is dedicated in-suite pathology (cryostat, lab tech, $80K-$150K capex) which cuts turnaround from 45-60 minutes to 15-25 minutes and adds a 4th case per surgeon-day.

2.3 Cosmetic Cash-Pay — The Margin Multiplier

Botox runs $13-$18/unit in suburban markets, $18-$25 in major metros, $25-$35 in top-tier urban derm practices. Wholesale cost is roughly $6.20/unit ($1,244 per 200-unit vial from Allergan), so gross margin is 50-75% before injector labor. Fillers (Juvederm, Restylane, RHA) wholesale at $280-$380/syringe, retail at $650-$1,100/syringe.

Bio-stimulators (Sculptra, Radiesse) carry the highest absolute margins — wholesale $350-$500, retail $900-$1,400 per session, typical patient buys a 3-session series.

The benchmark cosmetic mix for a hybrid practice is 30-40% of total revenue from cash-pay aesthetics. Below 20% you are leaving margin on the table; above 50% you are an aesthetic practice with a medical line, not a derm practice. Add energy-based devices (Moxi, BBL, Sofwave, Morpheus8) once cosmetic revenue clears $1.5M annually — device capex runs $80K-$220K and pays back in 14-22 months at typical per-treatment pricing of $500-$1,500.

3. Hiring & Retention — PA/NP Leverage Is the 2027 Multiplier

The dermatologist pipeline is structurally short — only ~13,000 board-certified dermatologists serve 330M Americans, and residency slots have grown <2%/year for a decade. The 2027 answer is PA/NP leverage, not "hire another MD".

3.1 The Provider Stack

The high-performance staffing model is 1 MD + 1-2 PA/NP per pod. 46% of dermatology practices already employ at least one PA or NP, and group practices over 3 MDs run at 54%+ PA/NP utilization. Dermatology PA total comp is $165K median, $190K at the 75th percentile, $225K+ at the 90th percentile, typically structured as $130K base + 15-25% of personal collections above threshold.

Derm NPs trend slightly lower at $140K-$160K total.

3.2 Recruiting Channel Reality

The two channels that actually fill PA/NP roles in 2027 are the Society of Dermatology Physician Assistants (SDPA) job board and direct outreach to PA program clinical coordinators. Indeed and ZipRecruiter underperform — derm PAs are not browsing generic boards. Time-to-fill for a derm PA in 2027 is 90-150 days; budget the search runway.

The cheapest pipeline is growing your own — host 1-2 PA students per quarter in a structured 6-week rotation, and roughly 20-30% convert to hires post-graduation at $15K-$25K signing bonus, less than half the cost of an external recruiter placement.

3.3 Retention — The $100K Replacement Cost

Replacing a tenured derm PA costs $80K-$120K (recruiting, ramp, lost production). The retention levers that actually work: production bonuses paid monthly (not annually), CME stipend of $3K-$5K/year, cosmetic injection training paid by the practice (Galderma and Allergan both run 2-day certification courses at $1,500-$2,500), and clear MD-to-partner or equity-track conversation by year 3 for top performers.

The single highest-leverage retention investment is scribe support — adding an AI scribe (ModMed Scribe, DAX Copilot, Suki) or a human scribe at $18-$24/hr typically lifts PA daily visit volume 15-25% and reduces evening-charting attrition risk.

3.4 Front-Desk and MA Compensation

The other half of staffing math is the non-provider team. Front-desk benchmark in 2027 is $19-$26/hr plus a $50-$150 per-signed-member enrollment bonus. Medical assistants run $22-$30/hr plus a photo-documentation production bonus in cosmetic-heavy practices.

Tenured MAs who assist Mohs, run cosmetic photo intake, and do patient education are worth 20-30% above market — the hardest role to replace.

4. Tech Stack — The 2027 Operating Spine

The EMR/PM choice is a 7-10 year decision and the single biggest tech bet a derm owner makes. The 2027 landscape has consolidated around four players for private derm.

4.1 EMR/PM Core

Modernizing Medicine EMA is the dermatology-specific market leader, cloud-based, iPad-first, dermatology-trained AI scribe (ModMed Scribe, trained on 750M+ derm encounters), strong photo-documentation, and integrated PM. Pricing: roughly $650-$900/provider/month plus $5K-$15K implementation.

Best for 3+ MD practices with mixed medical/cosmetic.

Nextech holds the AAD's only DataDerm Gold Recognition and won 2024 Best in KLAS for ambulatory specialty EHR. Strong TouchMD integration for cosmetic photo consults. Pricing typically $700-$1,100/provider/month. Best for cosmetic-heavy or surgical-heavy practices.

Practice Fusion is the budget option at ~$149/provider/month, ad-supported, weak on dermatology-specific templates and photo workflow. Survives as a solo-practice starter EMR; most practices outgrow it by year 2.

eClinicalWorks is generalist and cheaper ($449-$599/provider/month) but lacks derm-specific workflow; viable only if the owner has prior eCW familiarity.

4.2 Cosmetic / Med-Spa Layer

For cash-pay cosmetic, layer Aesthetic Record ($299-$499/month/location), Boulevard ($425+/month), or PatientNow ($410-$1,200/month) on top of the EMR. These handle before/after photo libraries, package/membership billing, online cosmetic booking, and Allē/ASPIRE integration that medical EMRs handle poorly.

4.3 Communications, Booking, Reviews

NexHealth ($299-$499/month) or Klara ($399-$599/month) for two-way patient SMS and online booking. Weave ($499/month/location) bundles phone, SMS, reviews, and payments — a strong consolidated bet for single-location practices. Phreesia ($300-$700/month) for digital intake and copay collection at check-in.

4.4 RCM and Billing

Waystar ($350-$600/month) for claims, eligibility, and denial management is the most common 2027 choice. Tebra ($150-$300/provider/month) is the budget alternative. Outsourced RCM via Coronis Health or R1 RCM typically runs 4-7% of collections and pays for itself if your in-house net collection rate is below 94%.

4.5 Analytics and Dashboarding

Most practices stop at EMR built-in reports and starve themselves of operating data. The 2027 standard is a weekly dashboard in Looker Studio (free) or Sigma, pulled via EMR API or scheduled CSV export, showing visits/day/provider, net collection rate, no-show rate, cosmetic %, membership count, reviews/month, and rebooked-visit %.

All-in cost: $0-$300/month plus 4-8 setup hours.

5. Retention & Recurring Revenue — The Membership Lock-In

Recurring revenue is the single largest valuation multiplier in 2027 derm M&A. Practices with 20%+ of cosmetic revenue from memberships trade at 10-12x EBITDA; practices without trade at 6-8x. Private equity buyers — **Forefront Dermatology (Partners Group), U.S.

Dermatology Partners (Abry Partners), Schweiger Dermatology, PhyNet, Frontier Dermatology** — explicitly underwrite the membership line.

5.1 The Aesthetic Membership Construct

The default 2027 membership tiers: Essentials at $99/month (1 Botox area per quarter, 10% off all other cosmetic services), Plus at $199/month (full-face Botox quarterly, 1 facial/quarter, 15% off), Elite at $399/month (Botox + 1 syringe filler/year + 4 facials, 20% off).

The math: at 300 active members at $150 blended ARPU, that is $45K/month in recurring revenue, $540K/year, and it pulls members into the practice 4x/year minimum where they buy add-ons.

5.2 Skincare Retail — The Underrated 10-15%

A well-run derm practice clears 10-15% of collections from professional skincare retail (SkinCeuticals, Skinbetter Science, EltaMD, Alastin). Wholesale margins are 40-50%; the typical patient who buys retail at the visit returns 2.3x more often than the patient who does not.

Stock 8-12 SKUs, train front desk on cross-sell scripts, and review monthly.

5.3 The Re-Care Engine

Annual skin exams are the medical recurring revenue line. Use the EMR recall function plus automated SMS at 11 months to drive re-booking. Benchmark: 65-75% of medical patients return within 14 months.

Below 60% indicates a broken recall workflow or weak patient experience. Add a Mohs post-op 6-month and 12-month total-body skin exam recall — these are clinically warranted AND they convert at 80%+ because the patient already trusts the practice with a cancer diagnosis.

6. Failure Modes — What Kills Private Derm Practices in 2027

The five failure modes that account for most struggling private derm practices, in rough order of how often they show up in a turnaround diagnostic.

6.1 Cosmetic Underbuild

Running <15% cosmetic revenue in a competitive metro leaves margin on the table and exposes the practice fully to Medicare and commercial fee-schedule compression. CMS dermatology codes lost ~2-3% in 2025 and another ~1.5% projected through 2027. Without a cosmetic offset, contribution margin compresses every year.

6.2 Front-End RCM Failure

Net collection rate below 92% quietly bleeds $200K-$500K/year out of a 3-MD practice. The fix is eligibility verification at booking + prior auth automation + same-week denial work — not "we should hire another biller". Outsourced RCM at 5-6% of collections beats most in-house teams below the $5M revenue mark.

6.3 PA/NP Turnover

Losing a tenured PA every 24 months instead of every 60 months means $400K+ in lost production over five years and recurring $100K replacement costs. The pattern is usually a flat base salary with a vague bonus — fix it with monthly production payouts and a written partner-track conversation in year 3.

6.4 Single-Vendor Cosmetic Lock-In

Practices that go 100% Allergan miss the Galderma toxin patient and vice versa. Carry both Botox and Dysport, both Juvederm and Restylane, and let injector preference and patient loyalty programs drive the choice per visit.

6.5 EMR Underinvestment

Staying on Practice Fusion or generalist EMR past $2M in revenue caps the practice. Photo workflow, cosmetic package billing, and AI scribe are the three EMA/Nextech features that pay back within 6-12 months at scale.

6.6 Compliance and State-Board Drift

Med-spa state regulation tightened in 2025-2026 — several states now require an MD/DO medical director, good-faith exam before injection, and written delegation agreements for RN injectors. Practices that scaled cosmetic on autopilot are seeing $5K-$50K state-board fines in 2026-2027 enforcement waves.

Audit state board rules every 12 months.

7. The 30/60/90 Day Operator Plan

A pragmatic 90-day plan for an owner-operator who just bought, inherited, or wants to reset a private derm practice.

7.1 Days 1-30 — Measure and Stabilize

Pull 12 months of provider production by CPT, net collection rate by payer, no-show rate by clinic day, review volume per location, and cosmetic-as-percent-of-revenue. Claim Google Business Profile at every location, install a review automation tool (Weave or Birdeye), and audit the EMR contract for renewal date and cancellation clause.

7.2 Days 31-60 — Plug the Leaks

Turn on online booking and two-way SMS (NexHealth or Klara), launch a Botox-and-Allē rebooking script at front desk, write a PA bonus restructure ($130K base + 15-20% of collections above $750K threshold, paid monthly), and stand up a basic membership pilot at one location with 50-target sign-ups.

7.3 Days 61-90 — Build the Recurring Line

Roll membership across all locations, launch Instagram cadence (4-6 posts/week, Reels weighted), add a second toxin (Dysport) and run a 30-day patient-choice test, schedule quarterly PCP referral lunches, and stand up a monthly KPI dashboard with the 7 numbers that matter: visits/day/provider, net collection rate, no-show rate, cosmetic %, membership count, reviews/month, NPS.

FAQ

Q: Should I buy ModMed EMA or Nextech if I'm a 2-MD private practice with a cosmetic line? A: ModMed EMA is the safer 2027 default — better mobile workflow, stronger AI scribe, lower per-provider cost. Pick Nextech if you are surgical-heavy (Mohs >3 cases/day) or your cosmetic line is already 40%+ of revenue and TouchMD photo consult is core to your sell.

Q: What's a realistic membership target for a 3-provider hybrid derm practice? A: 300-500 active members within 18 months is realistic; 600+ within 24 months is achievable with active enrollment scripts at every cosmetic visit. At $150 blended ARPU that is $45K-$75K/month in recurring revenue plus the add-on lift from increased visit frequency.

Q: How much should I pay a derm PA in 2027 to actually retain them? A: $130K base + 15-25% of personal collections above a $700K-$800K threshold, paid monthly, plus $3K-$5K CME, paid injection training, and a written partner-track timeline by year 3. Total comp lands at $165K-$220K for a productive PA.

Below $160K total in any metro, you will lose them to a PE platform within 18 months.

Q: Is private equity actually paying 10x EBITDA for derm practices in 2027? A: Platform practices (3+ MDs, $5M+ revenue, 20%+ cosmetic mix, 20%+ membership recurring revenue) trade at 10-12x EBITDA. Tuck-in single-location practices trade at 6-8x. The premium is recurring revenue + scalable PA model + clean RCM.

Practices below $2M revenue or <10% cosmetic mix typically clear 4-6x.

Q: What's the biggest 2027 regulatory risk to plan for? A: CMS dermatology code revaluation continues — expect another 1-2% fee compression through 2027, with E/M and pathology codes most exposed. State-level med-spa regulation is tightening — several states now require an MD/DO medical director on-site or via documented chart review; check your state board annually.

Compounded GLP-1 enforcement by FDA has reshaped what's legal to offer; stick to commercially available brand product.

Bottom Line

The 2027 private dermatology playbook is not "do more medical visits." It is mix engineering: keep medical at 55-65% of revenue for stability, drive Mohs to its room and pathology limits for high-margin insurance income, and build cosmetic to 25-35% with an aesthetic membership line that lands 20%+ of cosmetic revenue as recurring.

Run that mix on ModMed EMA or Nextech, leverage 2 PA/NPs per MD with monthly production bonuses, and own the local Google + Instagram surface at every location. Practices that hit this profile clear $1.6M-$2.0M per FTE physician, run at 45-50% overhead, and exit at 10-12x EBITDA when the owner is ready.

Sources

• Modernizing Medicine — EMA Dermatology product and pricing documentation, 2026
• Nextech — Dermatology PM/EMR pricing and AAD DataDerm Gold Recognition, 2026
• AAD (American Academy of Dermatology) — Workforce and PA/NP utilization surveys
• JCAD (Journal of Clinical and Aesthetic Dermatology) — Dermatology NP & PA Workforce Survey, compensation data
• FOCUS Investment Banking — Dermatology Practice Valuation 2025-2026 benchmarks
• Physician Growth Partners — State of Dermatology Private Equity white papers, 2024-2026
• Allergan Aesthetics (AbbVie) — Botox unit pricing, Allē loyalty program, 200-unit vial wholesale
• Galderma — Dysport/Restylane/Sculptra pricing and ASPIRE Rewards documentation
• Healio Dermatology / Dermatology Times — 2025-2026 industry coverage on PE consolidation and RCM
• CMS (Centers for Medicare & Medicaid Services) — 2025-2027 Physician Fee Schedule final rules for dermatology codes
• KLAS Research — 2024 Best in KLAS Ambulatory Specialty EHR rankings